What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Lung cancer, Internal medicine, Cancer, Oncology and Surgery are his primary areas of study.
His studies in Lung cancer integrate themes in fields like Randomized controlled trial, Cisplatin and Adenocarcinoma.
His studies in Hazard ratio, Chemotherapy, Clinical trial, Survival rate and Regimen are all subfields of Internal medicine research.
His Hazard ratio research includes themes of Gastroenterology, Placebo and Survival analysis.
The Chemotherapy study which covers Carcinoma that intersects with Proportional hazards model.
His Cancer research incorporates elements of Stage, Cancer research, Medical physics and Pathology.
His most cited work include:
- Erlotinib in previously treated non-small-cell lung cancer. (4713 citations)
- Erlotinib in lung cancer - molecular and clinical predictors of outcome. (1679 citations)
- Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer (1429 citations)
What are the main themes of his work throughout his whole career to date?
Lesley Seymour focuses on Internal medicine, Oncology, Clinical trial, Cancer and Lung cancer.
As part of his studies on Internal medicine, Lesley Seymour often connects relevant subjects like Surgery.
Lesley Seymour interconnects Gastroenterology and Adverse effect in the investigation of issues within Surgery.
His research in Oncology intersects with topics in Carboplatin, Cisplatin and Proportional hazards model.
He studied Clinical trial and Pharmacokinetics that intersect with Tolerability.
His studies deal with areas such as Adjuvant, Carcinoma, Randomized controlled trial and Adenocarcinoma as well as Lung cancer.
He most often published in these fields:
- Internal medicine (76.28%)
- Oncology (60.87%)
- Clinical trial (38.74%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (76.28%)
- Oncology (60.87%)
- Cancer (38.34%)
In recent papers he was focusing on the following fields of study:
Lesley Seymour mainly investigates Internal medicine, Oncology, Cancer, Lung cancer and Chemotherapy.
Lesley Seymour conducts interdisciplinary study in the fields of Internal medicine and In patient through his research.
His work carried out in the field of Oncology brings together such families of science as Clinical trial, Phases of clinical research, Proportional hazards model, Hazard ratio and Colorectal cancer.
His work investigates the relationship between Cancer and topics such as Randomized controlled trial that intersect with problems in Progression-free survival and Adjuvant therapy.
Lesley Seymour has included themes like Stage, KRAS, Carcinoma and Immunohistochemistry in his Lung cancer study.
His Chemotherapy study combines topics in areas such as Biomarker, Concomitant, Tolerability and Adjuvant.
Between 2015 and 2021, his most popular works were:
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (739 citations)
- RECIST 1.1—Update and clarification: From the RECIST committee (365 citations)
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer (147 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Cancer and Clinical trial.
His Internal medicine study focuses mostly on Nausea and Adverse effect.
The concepts of his Oncology study are interwoven with issues in Regimen, Colorectal cancer, Irinotecan and Phases of clinical research.
His Lung cancer research includes themes of Carcinoma, Surgery, Chemotherapy and Hazard ratio.
In his research, Drug development is intimately related to Randomized controlled trial, which falls under the overarching field of Cancer.
His Clinical trial research incorporates themes from KRAS, Medical physics and Erlotinib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
